Primary Myelofibrosis (PMF)
Also known as: Myelofibrosis, Primary / Myelofibrosis (PMF) / Primary Myelofibrosis (MF) / Primary Myelofibrosis / PMF / Osteomyelofibrosis / Myelosclerosis with myeloid metaplasia (disorder) / Myelofibrosis (disorder) / Myelosclerosis with myeloid metaplasia -RETIRED- / Myelosclerosis with myeloid metaplasia / Myelosclerosis with myeloid metaplasia (morphologic abnormality) / (Neoplasm of uncert behav of other lymphat and haematopoietic tissue) or (neoplasm of uncert behav of blood) or (idiopathic thrombocythaemia) or (megakaryocytic myelosclerosis) or (myelodysplasia)
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB12500 | Fedratinib | Fedratinib is indicated to treat adults with primary or secondary myelofibrosis that is either intermediate-2 or high risk. |
| DB08877 | Ruxolitinib | A kinase inhibitor used to treat various types of myelofibrosis, polycythemia vera in patients who have not responded to or cannot tolerate hydroxyurea, and to treat graft-versus-host disease in cases that are refractory to steroid treatment. |